December 26, 2014
Sumitomo Dainippon Pharma announced on December 25 that the efficacy of its atypical antipsychotic lurasidone HCl (overseas brand name: Latuda) was confirmed in a PIII Asian clinical study in patients with schizophrenia. Based on the results of the study, the...read more